Medication-related osteonecrosis of the jaw
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. All included patients were diagnosed with MRONJ. (1) current or previous treatment with a BMA or angiogenic inhibitor; (2) exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region and that has persisted for longer than 8 weeks, and (3) no history of radiation therapy to the jaws or metastatic disease to the jaws. 2. Patients with stage 2 or stage 3 were included. (1) stage 2: Stage 2: Exposed and necrotic bone or fistulas that probe to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage. (2) stage 3: Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone (ie, inferior border and ramus in mandible maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral or oral nasal communication, or osteolysis extending to the inferior border of the mandible or sinus floor.
Exclusion criteria
Exclusion criteria: Patients with developmental maxillofacial anomalies, previous radiation in the head and neck area and jaw bone tumors were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| demographic: age, gender, smoking, cancer types, osteoporosis, general diseases, tooth extraction, denture use, periodontal disease, chemotherapy use, targeted drugs use, endocrine drugs use, immune suppressive drugs;lesion location;radiological data (sequestrum size and bone density of lesion); | — |
Countries
China
Contacts
Department of Oral Surgery, Shanghai Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine